A multi-center post-market clinical study to confirm safety and performance of PuraStat® in the management of bleeding during open liver resection

Published:October 06, 2021DOI:



      PuraStat® is a non-bioactive haemostatic agent that has demonstrated efficacy in a number of different surgical procedures. We performed a prospective multi-centre post-market study to evaluate the efficacy and safety of PuraStat® in liver resections performed for metastatic tumors.


      This was a prospective cohort study. Patients undergoing liver resection for metastatic tumor were screened for eligibility, and included if they were ≥18 years old, undergoing open liver resection, had normal liver function, and required application of PuraStat® for haemostasis where standard haemostatic techniques were either insufficient or impractical. The primary endpoint was “time to haemostasis” (TTH). Secondary endpoints included blood loss, total postoperative drainage volume, transfusion of blood products, and ease of use.


      Eighty patients were included for analysis in the intention to treat population. 207 bleeding sites were treated with PuraStat. Of these, 190 (91.7%) bleeding sites reached haemostasis after PuraStat® application. Mean TTH (mm:ss) was 1:01 (SD 1:06, range 0:09–6:55). Ease of use of the product was described as either “excellent” or “good” in 78 (98.8%) patients. No serious adverse events were identified.


      This study confirms the safety, efficacy and ease of use of PuraStat® in the management of bleeding in liver surgery.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to HPB
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Imamura H.
        • Seyama Y.
        • Kokudo N.
        • Maema A.
        • Sugawara Y.
        • Sano K.
        • et al.
        One thousand fifty-six hepatectomies without mortality in 8 years.
        Arch Surg. 2003; 138 (; discussion 206): 1198-1206
        • Alfieri S.
        • Carriero C.
        • Caprino P.
        • Di Giorgio A.
        • Sgadari A.
        • Crucitti F.
        • et al.
        Avoiding early postoperative complications in liver surgery. A multivariate analysis of 254 patients consecutively observed.
        Dig Liver Dis. 2001; 33: 341-346
        • Belghiti J.
        • Hiramatsu K.
        • Benoist S.
        • Massault P.
        • Sauvanet A.
        • Farges O.
        Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection.
        J Am Coll Surg. 2000; 191: 38-46
        • Jamieson G.G.
        • Corbel L.
        • Campion J.P.
        • Launois B.
        Major liver resection without a blood transfusion: is it a realistic objective?.
        Surgery. 1992; 112: 32-36
        • Farges O.
        • Goutte N.
        • Bendersky N.
        • Falissard B.
        • Group A.C.-F.H.S.
        Incidence and risks of liver resection: an all-inclusive French nationwide study.
        Ann Surg. 2012; 256 (discussion -5): 697-704
        • de Haas R.J.
        • Wicherts D.A.
        • Andreani P.
        • Pascal G.
        • Saliba F.
        • Ichai P.
        • et al.
        Impact of expanding criteria for resectability of colorectal metastases on short- and long-term outcomes after hepatic resection.
        Ann Surg. 2011; 253: 1069-1079
        • Chapman W.C.
        • Clavien P.A.
        • Fung J.
        • Khanna A.
        • Bonham A.
        Effective control of hepatic bleeding with a novel collagen-based composite combined with autologous plasma: results of a randomized controlled trial.
        Arch Surg. 2000; 135 (; discussion 5): 1200-1204
        • Clark Jr., W.R.
        • Leather R.P.
        Hemostasis during liver resections.
        Surgery. 1970; 67: 556-557
        • Lee M.F.
        • Ma Z.
        • Ananda A.
        A novel haemostatic agent based on self-assembling peptides in the setting of nasal endoscopic surgery, a case series.
        Int J Surg Case Rep. 2017; 41: 461-464
        • Masuhara H.
        • Fujii T.
        • Watanabe Y.
        • Koyama N.
        • Tokuhiro K.
        Novel infectious agent-free hemostatic material (TDM-621) in cardiovascular surgery.
        Ann Thorac Cardiovasc Surg. 2012; 18: 444-451
        • Yoshida M.
        • Goto N.
        • Kawaguchi M.
        • Koyama H.
        • Kuroda J.
        • Kitahora T.
        • et al.
        Initial clinical trial of a novel hemostat, TDM-621, in the endoscopic treatments of the gastric tumors.
        J Gastroenterol Hepatol. 2014; 29: 77-79
        • Schwartz M.
        • Madariaga J.
        • Hirose R.
        • Shaver T.R.
        • Sher L.
        • Chari R.
        • et al.
        Comparison of a new fibrin sealant with standard topical hemostatic agents.
        Arch Surg. 2004; 139: 1148-1154
        • Frilling A.
        • Stavrou G.A.
        • Mischinger H.J.
        • de Hemptinne B.
        • Rokkjaer M.
        • Klempnauer J.
        • et al.
        Effectiveness of a new carrier-bound fibrin sealant versus argon beamer as haemostatic agent during liver resection: a randomised prospective trial.
        Langenbeck’s Arch Surg. 2005; 390: 114-120
        • Fischer L.
        • Seiler C.M.
        • Broelsch C.E.
        • de Hemptinne B.
        • Klempnauer J.
        • Mischinger H.J.
        • et al.
        Hemostatic efficacy of TachoSil in liver resection compared with argon beam coagulator treatment: an open, randomized, prospective, multicenter, parallel-group trial.
        Surgery. 2011; 149: 48-55
        • Verhoef C.
        • Singla N.
        • Moneta G.
        • Muir W.
        • Rijken A.
        • Lockstadt H.
        • et al.
        Fibrocaps for surgical hemostasis: two randomized, controlled phase II trials.
        J Surg Res. 2015; 194: 679-687
        • Ollinger R.
        • Mihaljevic A.L.
        • Schuhmacher C.
        • Bektas H.
        • Vondran F.
        • Kleine M.
        • et al.
        A multicentre, randomized clinical trial comparing the Veriset haemostatic patch with fibrin sealant for the management of bleeding during hepatic surgery.
        HPB. 2013; 15: 548-558
        • Lewis K.M.
        • Li Q.
        • Jones D.S.
        • Corrales J.D.
        • Du H.
        • Spiess P.E.
        • et al.
        Development and validation of an intraoperative bleeding severity scale for use in clinical studies of hemostatic agents.
        Surgery. 2017; 161: 771-781
        • Strosberg J.
        • El-Haddad G.
        • Wolin E.
        • Hendifar A.
        • Yao J.
        • Chasen B.
        • et al.
        Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors.
        N Engl J Med. 2017; 376: 125-135
        • Final Clinical Study Report
        A single-centre, single arm post-market clinical follow-up to confirm the safety and performance of PuraStat® absorbable haemostatic material for the management of bleeding after left ventricular assist device (LVAD) implantation (PuraStat-004).
        04 May 2018 (Unpublished report)
        Version: Version 1.4
      1. A multi-center, single arm post-market clinical study to confirm safety and performance of PuraStat® absorbable haemostatic material for the management of bleeding in vascular surgery. Identifier : NCT03103282. Unpublished data.

        • Figueras J.
        • Llado L.
        • Miro M.
        • Ramos E.
        • Torras J.
        • Fabregat J.
        • et al.
        Application of fibrin glue sealant after hepatectomy does not seem justified: results of a randomized study in 300 patients.
        Ann Surg. 2007; 245: 536-542